Pilar González-De-La-Aleja

Pilar González-De-La-Aleja

Auto-generated profile, based on publicly available information

Pilar González-De-La-Aleja

Unit of infectious Diseases Dr. Balmis General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Avda Pintor Baeza, 12, Alicante 03010, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of Infection
Verified
Journal Article
Closed access
OMOscar Moreno-Perez
Oscar Moreno-Perez
EMEsperanza Merino
Esperanza Merino
Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
Jose-Manuel Ramos-Rincon
Mariano AndrésMariano Andrés
Mariano Andrés
Jose-Manuel Ramos-RinconJose-Manuel Ramos-Rincon
Jose-Manuel Ramos-Rincon
JGJoan Gil
Joan Gil

30 April 2022 in Anaerobe
Verified
Journal Article
Closed access
NMNicolás Merchante
Nicolás Merchante
PCPablo Chico-Sánchez
Pablo Chico-Sánchez
EMEsther Márquez-Saavedra
Esther Márquez-Saavedra
GRGerónima Riera
Gerónima Riera
MRMaría del Rocío Herrero del Rio
María del Rocío Herrero del Rio
EMEsperanza Merino
Esperanza Merino

30 March 2023 in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
Verified
Journal Article
Closed access
Hector Pinargote-CelorioHector Pinargote-Celorio
Hector Pinargote-Celorio
SOSilvia Otero-Rodriguez
Silvia Otero-Rodriguez
PGPilar González-De-La-Aleja
Pilar González-De-La-Aleja
JRJuan Carlos Rodríguez
Juan Carlos Rodríguez
ECEduardo Climent
Eduardo Climent
EMEsperanza Merino
Esperanza Merino

6 December 2022 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
Hector Pinargote-CelorioHector Pinargote-Celorio
Hector Pinargote-Celorio
SOSilvia Otero-Rodriguez
Silvia Otero-Rodriguez
PGPilar González-De-La-Aleja
Pilar González-De-La-Aleja
JRJuan Carlos Rodríguez
Juan Carlos Rodríguez
ECEduardo Climent
Eduardo Climent
EMEsperanza Merino
Esperanza Merino

7 October 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
Hector Pinargote-CelorioHector Pinargote-Celorio
Hector Pinargote-Celorio
OMOscar Moreno-Perez
Oscar Moreno-Perez
PGPilar González-De-La-Aleja
Pilar González-De-La-Aleja
JLJara Llenas-García
Jara Llenas-García
PPPedro María Martínez Pérez-Crespo
Pedro María Martínez Pérez-Crespo
EMEsperanza Merino
Esperanza Merino
Background: The effectiveness of the early treatment for antiviral agents in SARS-CoV-2 infection is closely related to patient comorbidities. Data on effectiveness in immunocompromised patients are limited, with reports involving highly heterogeneous and not well-defined populations. We aimed to assess the effectiveness of treatment in reducing hospitalizations in a real-world cohort of severely immunocompromised COVID-19 outpatients. Patients and methods: We conducted a multicentre, retrospective, observational cohort study of immunocompromised outpatients attended in infectious diseases departments from 1 January to 31 December 2022. Propensity score matching (PSM) multivariable logistic regression models were used to estimate the adjusted odds ratio [(aOR, 95% confidence interval (CI)] for the association between antiviral prescription and outcome (COVID-19–related hospitalization up to Day 90). Results: We identified 746 immunocompromised outpatients with confirmed SARS-CoV-2 infection. After eligibility criteria and PSM, a total of 410 patients were analysed: 205 receiving treatment (remdesivir, sotrovimab or nirmatrelvir/ritonavir) and 205 matched controls. Fifty-two patients required at least one COVID-19–related hospitalization 8 (3.9%) versus 44 (21.5%) in the antiviral and matched control cohorts, respectively. There were 13 deaths at 90 days, of which only 4 were COVID-19–related and none in the antiviral treatment group. After adjustment for residual confounders, the use of early therapy was associated with a protective effect on the risk of hospitalization [aOR 0.13 (0.05–0.29)], as was the use of biological immunomodulators [aOR 0.27 (0.10–0.74)], whereas chronic obstructive pulmonary disease [aOR 4.65 (1.09–19.69)] and anti-CD20 use [aOR 2.76 (1.31–5.81)] increased the odds. Conclusions: Early antiviral treatment was associated with a reduced risk of COVID-19–related hospitalization in ambulatory severely immunocompromised COVID-19 patients.

25 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
ELEster Lobato-Martínez
Ester Lobato-Martínez
JMJavier Muriel-Serrano
Javier Muriel-Serrano
EGElena García-Payá
Elena García-Payá
PGPilar Gonzalez-De-La-Aleja
Pilar Gonzalez-De-La-Aleja
RGRaquel Garcia-Sevila
Raquel Garcia-Sevila
RSRosario Sanchez-Martinez
Rosario Sanchez-Martinez
Background and Objectives: The aim of the following cross-sectional study is to determine the association between human leukocyte antigen (HLA) alleles and outcomes in patients presenting to the emergency department (ED) with SARS-CoV-2 infection. Methods and Materials: Genotyping was made using the Axiom Human Genotyping SARS-CoV-2 Research Array. Statistical analysis was made with Fisher’s exact test and multivariable logistic regression, adjusted for sex, age and clinical variables. Results: Of 190 patients, 11.1% were discharged from the ED; 57.9% were admitted to the COVID-19 ward, without intensive care unit (ICU) admission; 15.3% survived an ICU admission; and 15.8% died. After multivariable analysis, two HLA alleles protected against hospital admission (HLA-C*05:01, adjusted odds ratio [aOR] 0.2, 95% confidence interval [CI] 0.055–0.731; and HLA-DQB1*02:02, aOR 0.046, CI 0.002–0.871) and one was associated with higher risk for ICU admission or death (HLA-DQA1*05:01, aOR 2.517, CI 1.086–5.833). Conclusions: In this population, HLA-C*05:01 and HLA-DQB1*02:02 are associated with a protective effect against hospital admission and HLA-DQA1*05:01 is associated with higher risk of ICU admission or death in the multivariable analysis. This may help stratify risk in COVID-19 patients.